cfDNA Assay Prospective Observational Validation for Early Cancer Detection and Minimal Residual Disease

Summary

This is an observational case-control study to train and validate a genome-wide methylome enrichment platform to detect multiple cancer types and to differentiate amongst cancer types. The cancers included in this study are brain, breast, bladder, cervical, colorectal, endometrial, esophageal, gastric, head and neck, hepatobiliary, leukemia, lung, lymphoma, multiple myeloma, ovarian, pancreatic, prostate, renal, sarcoma, and thyroid. These cancers were selected based on their prevalence and mortality to maximize impact on clinical care.

Shortened from the sponsor's brief summary. View official record on ClinicalTrials.gov

Conditions studied

• Brain Cancer
• Breast Cancer
• Bladder Cancer
• Cervical Cancer
• Colorectal Cancer
• Endometrial Cancer
• Esophageal Cancer
• Stomach Cancer
• Head and Neck Cancer
• Hepatobiliary Cancer
• Leukemia
• Lung Cancer
• Lymphoma
• Multiple Myeloma
• Ovarian Cancer
• Pancreatic Cancer
• Prostate Cancer
• Renal Cancer
• Sarcoma
• Thyroid Cancer

Eligibility basics and study details

Study type

Observational

Phase

Not applicable

Ages

40 years and older

Sex

All

Healthy volunteers

Accepted

Sponsor

Adela, Inc

Last updated on ClinicalTrials.gov

January 20, 2026

These are the basic criteria only. The full inclusion and exclusion criteria are on the official record, and the study team decides who can take part.

US recruiting sites